What is Zacks Research’s Estimate for Integer Q1 Earnings?

Integer Holdings Corporation (NYSE:ITGR) – Analysts at Zacks Research decreased their Q1 2026 earnings per share (EPS) estimates for shares of Integer in a research report issued on Thursday, November 13th. Zacks Research analyst Team now anticipates that the medical equipment provider will post earnings per share of $1.39 for the quarter, down from their prior estimate of $1.58. The consensus estimate for Integer’s current full-year earnings is $6.01 per share.

A number of other brokerages have also weighed in on ITGR. Raymond James Financial reaffirmed an “outperform” rating and set a $95.00 target price (down previously from $143.00) on shares of Integer in a research note on Friday, October 24th. Piper Sandler cut their price objective on Integer from $155.00 to $82.00 and set an “overweight” rating on the stock in a research report on Friday, October 24th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Integer in a report on Friday, October 31st. KeyCorp decreased their target price on Integer from $145.00 to $133.00 and set an “overweight” rating for the company in a research report on Tuesday, October 21st. Finally, Citigroup dropped their price target on Integer from $77.00 to $69.00 and set a “neutral” rating on the stock in a research report on Monday, November 3rd. Four research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $96.75.

Integer Trading Down 0.0%

Integer stock traded down $0.01 during mid-day trading on Friday, reaching $68.04. 60,814 shares of the company traded hands, compared to its average volume of 604,373. The company has a debt-to-equity ratio of 0.70, a current ratio of 3.71 and a quick ratio of 2.45. Integer has a 52-week low of $62.00 and a 52-week high of $146.36. The firm has a market capitalization of $2.38 billion, a price-to-earnings ratio of 28.41, a P/E/G ratio of 0.60 and a beta of 0.95. The firm’s 50 day moving average price is $92.45 and its 200 day moving average price is $107.61.

Integer (NYSE:ITGR) last announced its earnings results on Thursday, October 23rd. The medical equipment provider reported $1.79 EPS for the quarter, beating analysts’ consensus estimates of $1.68 by $0.11. Integer had a return on equity of 12.84% and a net margin of 4.75%.During the same quarter in the prior year, the firm earned $1.43 earnings per share. The business’s quarterly revenue was up 8.4% compared to the same quarter last year. Integer has set its FY 2025 guidance at 6.290-6.430 EPS.

Hedge Funds Weigh In On Integer

Hedge funds have recently added to or reduced their stakes in the company. Alliancebernstein L.P. lifted its position in Integer by 885.1% in the 2nd quarter. Alliancebernstein L.P. now owns 1,106,091 shares of the medical equipment provider’s stock valued at $136,016,000 after acquiring an additional 993,810 shares in the last quarter. Massachusetts Financial Services Co. MA bought a new position in shares of Integer during the third quarter valued at $41,938,000. William Blair Investment Management LLC purchased a new stake in shares of Integer during the third quarter valued at $28,459,000. Tributary Capital Management LLC boosted its position in shares of Integer by 92.6% during the third quarter. Tributary Capital Management LLC now owns 499,776 shares of the medical equipment provider’s stock valued at $51,642,000 after buying an additional 240,226 shares during the last quarter. Finally, Nuveen LLC bought a new stake in Integer in the 1st quarter worth about $17,634,000. 99.29% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Integer news, VP Tommy P. Thomas sold 884 shares of the business’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $70.15, for a total value of $62,012.60. Following the sale, the vice president directly owned 3,596 shares of the company’s stock, valued at approximately $252,259.40. The trade was a 19.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Diron Smith bought 1,116 shares of the business’s stock in a transaction dated Friday, November 7th. The stock was bought at an average cost of $67.19 per share, for a total transaction of $74,984.04. Following the completion of the purchase, the executive vice president owned 7,698 shares of the company’s stock, valued at approximately $517,228.62. The trade was a 16.96% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 5,843 shares of company stock worth $384,771 over the last three months. 2.16% of the stock is owned by corporate insiders.

Integer declared that its board has initiated a stock buyback plan on Tuesday, November 4th that authorizes the company to buyback $200.00 million in outstanding shares. This buyback authorization authorizes the medical equipment provider to reacquire up to 8.3% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board believes its shares are undervalued.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.